Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intravenous Liposomal Alendronate Infusion in Subjects Undergoing Bare Metal Coronary Stent Implantation.

Trial Profile

Intravenous Liposomal Alendronate Infusion in Subjects Undergoing Bare Metal Coronary Stent Implantation.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alendronic acid (Primary) ; Alendronic acid (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms BLAST
  • Sponsors BIOrest

Most Recent Events

  • 19 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
  • 21 Sep 2010 Primary endpoint 'In-stent late loss' has not been met, according to results presented at the 22nd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
  • 21 Sep 2010 Top-line results presented at the 22nd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top